Advanced search
Publication Cover
Expert Opinion on Orphan Drugs Volume 2, 2014 - Issue 12
Submit an article Journal homepage
48
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Decitabine treatment of extramedullary relapse in one patient with T-ALL transformed from myelodysplastic syndrome after allo-PBSCT

Yong YouHuazhong University of Science and Technology, Institution of Hematology, Union Hospital, Tongji Medical College, Jiefang Road 1277#, Jianghan District, Wuhan, Hubei Province 430022, China+86 15 802772188; +86 27 85726387; [email protected]
,
Zhaodong ZhongHuazhong University of Science and Technology, Institution of Hematology, Union Hospital, Tongji Medical College, Jiefang Road 1277#, Jianghan District, Wuhan, Hubei Province 430022, China+86 15 802772188; +86 27 85726387; [email protected]
,
Jieke CuiHuazhong University of Science and Technology, Institution of Hematology, Union Hospital, Tongji Medical College, Jiefang Road 1277#, Jianghan District, Wuhan, Hubei Province 430022, China+86 15 802772188; +86 27 85726387; [email protected]
,
Lingli ZouHuazhong University of Science and Technology, Institution of Hematology, Union Hospital, Tongji Medical College, Jiefang Road 1277#, Jianghan District, Wuhan, Hubei Province 430022, China+86 15 802772188; +86 27 85726387; [email protected]
,
Ping ZouHuazhong University of Science and Technology, Institution of Hematology, Union Hospital, Tongji Medical College, Jiefang Road 1277#, Jianghan District, Wuhan, Hubei Province 430022, China+86 15 802772188; +86 27 85726387; [email protected]
&
Min ZhangHuazhong University of Science and Technology, Institution of Hematology, Union Hospital, Tongji Medical College, Jiefang Road 1277#, Jianghan District, Wuhan, Hubei Province 430022, China+86 15 802772188; +86 27 85726387; [email protected]
Pages 1249-1253 | Published online: 08 Nov 2014

Bibliography

  • Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012;26:1286-92
  • Yang H, Kadia T, Xiao L, et al. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 2009;113:1892-8
  • Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood 2014;123:829-36
  • Stathis A, Hotte SJ, Chen EX, et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Clin Cancer Res 2011;17:1582-90
  • Blum KA, Liu Z, Lucas DM, et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol 2010;150:189-95
  • Algarni AA, Akhtari M, Fu K. Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature. Case Rep Hematol 2012;2012:207537
  • Harris AC, Kitko CL, Couriel DR, et al. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 2013;98:179-84
  • Yánez L, Bermúdez A, Richard C, et al. Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia 2009;23:1342-3
  • Ravandi F, Kantarjian H, Cohen A, et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 2001;27:1221-5
  • Blum KA, Liu Z, Lucas DM, et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol 2010;150:189-95
  • Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009;15:3881-8
  • Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009;115:1899-905
  • Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013;27:1229-35
  • Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylation agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010;116:129-39

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.